• Kiniksa entered a deed of waiver with Baker Bros. Advisors covering Baker Brothers Life Sciences, L.P. and 667, L.P.
• The shareholders waived conversion rights for Class A1 or Class B1 shares if conversion would lift voting control above 49.9%.
• Changes to the deed generally require approval from holders of at least 75% of outstanding ordinary shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001730430-26-000025), on May 26, 2026, and is solely responsible for the information contained therein.